This journal article is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals managing cancer patients. The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for healthcare teams. The article covers updates to the NCCN Guidelines for Bladder Cancer, including changes in the WHO Classification of Tumours: Urinary and Male Genital Tumours, new and emerging treatment options for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and updates to systemic therapy recommendations for advanced or metastatic disease. The article also discusses the role of immunotherapy, antibody-drug conjugates, and targeted therapies in the treatment of bladder cancer. Participants will learn about integrating these updates into their professional practice and understanding the rationale behind the decision-making process for developing the NCCN Guidelines. The article includes disclosures of relevant financial relationships and provides detailed information on the treatment options and their efficacy, safety, and clinical trial data.This journal article is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals managing cancer patients. The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for healthcare teams. The article covers updates to the NCCN Guidelines for Bladder Cancer, including changes in the WHO Classification of Tumours: Urinary and Male Genital Tumours, new and emerging treatment options for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and updates to systemic therapy recommendations for advanced or metastatic disease. The article also discusses the role of immunotherapy, antibody-drug conjugates, and targeted therapies in the treatment of bladder cancer. Participants will learn about integrating these updates into their professional practice and understanding the rationale behind the decision-making process for developing the NCCN Guidelines. The article includes disclosures of relevant financial relationships and provides detailed information on the treatment options and their efficacy, safety, and clinical trial data.